The TOURMALINE-MM1 study: results and expert insights
|
|
- Cornelia Hodges
- 5 years ago
- Views:
Transcription
1 The TOURMALINE-MM1 study: results and expert insights Professor Faith Davies UAMS Myeloma Institute, Arkansas, USA This educational meeting was organised and fully funded by Takeda UK Ltd. Takeda medicines were discussed during this meeting. Prescribing Information is available on final slide The views expressed during this presentation are those of the speaker Zinc code: UK/IXA/1711/0062a. Date of preparation: December 2017
2 TOURMALINE-MM1 study design 1 Phase III global, double-blind, randomised, placebo-controlled study design 1 Primary endpoint: PFS Key secondary endpoints: OS OS in patients with del(17p) Response and progression (IMWG 2011 criteria 2 ) assessed by an IRC blinded to both treatment and investigator assessment Stratification: Prior therapy: 1 vs. 2 or 3 ISS: I or II vs. III Prior PI exposure: yes vs. no *10 mg for patients with creatinine clearance 60 or 50 ml/min, depending on local label/practice. IMWG, International Myeloma Working Group; IRC, independent review committee; ISS, International Staging System; OS, overall survival; PFS, progression-free survival; PI, proteasome inhibitor; RRMM, relapsed/refractory multiple myeloma. 1. Moreau P et al. N Engl J Med 2016;374: ; 2. Rajkumar S et al. Blood 2011;117:
3 Patient eligibility criteria Key inclusion criteria: Confirmed diagnosis of MM Measurable disease by at least one of: Serum protein electrophoresis Urine protein electrophoresis Free light chain assay Received 1 3 prior treatments Relapsed, relapsed and refractory, or primary refractory disease* Creatinine clearance 30 ml/min Key exclusion criteria: Refractory to previous PI-based or lenalidomide-based treatment *Including primary refractory patients (i.e., patients refractory to all prior therapies). Refractory = PD on treatment or within 60 days after last dose of therapy. MM, multiple myeloma; PD, progressive disease; PI, proteasome inhibitor. Moreau P et al. N Engl J Med 2016;374:
4 722 patients enrolled at 147 study centres in 26 countries Demographics Ixazomib-Rd (n=360) Placebo-Rd (n=362) Median age, years Gender, male/female, % 58/42 56/44 Number of prior lines of therapy, % 1* or 3* Prior PI*, % Prior IMiD, % Prior stem cell transplant, % Relapsed, % Refractory, % Relapsed and refractory, % High-risk cytogenetics, % ISS stage I or II*, % ISS stage III*, % Creatinine clearance <60 ml/min *Stratification factor; High-risk cytogenetic abnormalities were detected by fluorescence in situ hybridization (FISH) analysis and were defined as patients with del(17), t(4;14) or t(14;16). IgA, immunoglobulin A; IgG, immunoglobulin G; IMiD, immunomodulatory drug; ISS, International Staging System; PI, proteasome inhibitor; Rd, lenalidomide-dexamethasone. Moreau P et al. N Engl J Med 2016;374:
5 TOURMALINE-MM1: Clinical efficacy
6 First interim analysis: median follow-up of ~15 months Significant 35% improvement was seen in median PFS * with ixazomib-rd vs. placebo-rd Median PFS (primary endpoint): Ixazomib-Rd: 20.6 months Placebo-Rd: 14.7 months Probability of PFS Number of patients at risk: Ixazomib-Rd Placebo-Rd Median follow-up: ~15 months Log-rank test p=0.01 Hazard ratio (95% CI): 0.74 (0.59; 0.94) Number of events: ixazomib-rd 129; placebo-rd 157 Time from randomisation (months) *At first and final PFS analysis. Any subsequent interim analysis of PFS is non-inferential. CI, confidence interval; PFS, progression-free survival; Rd, lenalidomide-dexamethasone. Moreau P et al. N Engl J Med 2016;374:
7 First interim analysis: median follow-up of ~15 months Ixazomib-Rd extends PFS across a broad group of patients vs. placebo-rd 1,2 n Median PFS (months) Variable * Subgroup Ixazomib-Rd Placebo-Rd Ixazomib-Rd Placebo-Rd HR TOURMALINE-MM1 was not powered to assess efficacy in any specific subgroups, and as multiple myeloma 65 is 168 a heterogeneous disease, 14.1 benefit may vary across > subgroups1,2 > All patients ALL Age (years) ISS stage Cytogenetic risk I or II III Standard-risk High-risk Number of prior therapies 1 2 or NE Proteasome inhibitor Exposed Naive NE Prior IMiD therapy Exposed Naive NE Refractory to last prior therapy Yes No NE 20.6 NE Relapsed or refractory Relapsed Refractory Relapsed & Refractory NE NE Baseline CrCl group <50 ml/min 50 ml/min Figure adapted from Moreau P et al and NINLARO Summary of Product Characteristics 2. *TOURMALINE-MM1 was not powered to assess efficacy in any specific subgroups Favours ixazomib-rd Favours placebo-rd CrCL, creatinine clearance; HR, hazard ratio; IMiD, immunomodulatory drug; ISS, International Staging System; NE, not estimable; PFS, progression-free survival; Rd, lenalidomide-dexamethasone. 1. Moreau P et al. N Engl J Med 2016;374: ; 2. NINLARO (ixazomib capsules) Summary of Product Characteristics March 2017.
8 PFS is prolonged with ixazomib-rd vs. placebo-rd regardless of prior therapies Previous therapy Subgroup Median PFS, months Ixazomib-Rd Placebo-Rd HR 95% CI Prior PI Prior bortezomib Prior IMiD Prior lenalidomide Prior therapies Exposed (n=503) ( ) Naïve (n=219) NE ( ) Exposed (n=498) ( ) Naïve (n=224) NE ( ) Exposed (n=397) NE ( ) Naïve (n=325) ( ) Exposed (n=88) NE ( ) Naïve (n=634) ( ) 1 (n=425) ( ) 2 or 3 (n=297) NE ( ) CI, confidence interval; HR, hazard ratio; IMiD, immunomodulatory drugs; NE, not estimable; PFS, progression-free survival; PI, proteasome inhibitor; Rd, lenalidomide-dexamethasone. Mateos MV et al. Haematologica 2017; pii: haematol [E-pub ahead of print].
9 Efficacy in IA1 and IA2 in patients who have received 2 or 3 prior lines of therapy 1,2 First interim analysis Ixazomib-Rd (n=361), % Placebo-Rd (n=359), % Median PFS, months NE 12.9 Median OS, months NE NE Second interim analysis Median PFS, months Median OS, months NE NE HR (95% CI) 0.58 ( ) 0.62 ( ) 0.62 ( ) 0.65 ( ) CI, confidence interval; HR, hazard ratio; IA1, first interim analysis; IA2, second interim analysis; NE, not estimable; OS, overall survival; PFS progression free survival. 1. Takeda data on file - UK/DF/1710/0016; 2. Mateos MV et al. Haematologica 2017; pii: haematol [E-pub ahead of print].
10 Ixazomib-Rd significantly improves PFS vs. placebo-rd in patients who have received 2 or 3 prior lines of therapy *1,2 Primary PFS analysis (IA1) 15 months follow-up OS analysis (IA2) 23 months follow-up Ixazomib-Rd Placebo-Rd Ixazomib-Rd Placebo-Rd HR: 0.58 (95% CI 0.40, 0.84; p=0.0033) HR: 0.65 (95% CI 0.41, 1.02; p=0.0569) *The number of prior therapies (1 vs. 2 or 3) was a pre-specified subgroup and stratification factor in the TOURMALINE-MM1 trial. 3 CI, confidence interval; HR, hazard ratio; IA1, first interim analysis; IA2, second interim analysis; OS, overall survival; PFS progression free survival; Rd, lenalidomide-dexamethasone. 1. Takeda data on file - UK/DF/17010/0015; 2. Mateos MV et al. Haematologica 2017; pii: haematol [E-pub ahead of print]; 3. Moreau P et al. N Engl J Med 2016;374:
11 First interim analysis: median follow-up of ~15 months Ixazomib-Rd maintains PFS in patients with high-risk cytogenetics, including those with del(17p) 1,2 Median PFS, months All patients (N=722) Ixazomib-Rd Placebo-Rd 15.6 Standard-risk patients All high-risk patients Patients with del(17p) (n=415) (n=137) (n=69) Figure modified from Avet-Loiseau et al. 2 *p<0.05 for comparison between regimens. Alone or in combination with t(4;14) or t(14;16). Data not included on patients with t(14:16) alone due to small numbers (n=7). HR, hazard ratio; PFS, progression-free survival; Rd, lenalidomide-dexamethasone. 1. Moreau P et al. N Engl J Med 2016;374: ; 2. Avet-Loiseau H et al. European Hematology Association 22 nd Congress 2016; Poster P269. HR All patients * Standard-risk patients 0.640* All high-risk patients * Patients with del(17p) TOURMALINE-MM1 was not powered to assess efficacy in any specific subgroups
12 First interim analysis: median follow-up of ~15 months Improved response rates, TTP, and durable responses are seen with ixazomib-rd vs. placebo-rd Response rates Ixazomib-Rd (n=360) Placebo-Rd (n=362) p value Confirmed ORR, % p=0.04 VGPR,* % p=0.01 CR, % 12 7 p=0.02 PR, % VGPR,* % Median time to response, months p=0.009 Median duration of response ( PR), months Median time to disease progression, months p=0.007 *VGPR is a subset of PR. CR, complete response; ORR, overall response rate; PR, partial response; Rd, lenalidomide-dexamethasone; TTP, time to progression; VGPR, very good partial response. Moreau P et al. N Engl J Med 2016;374:
13 Responses deepened with continued ixazomib-rd treatment *The duration of one cycle of ixazomib-rd is 28 days. CR, complete response; PR, partial response; Rd, lenalidomide-dexamethasone; VGPR, very good partial response. Adapted from Moreau P et al. N Engl J Med 2016;374:
14 A later response to therapy is not detrimental to overall outcomes Outcomes for patients in the TOURMALINE-MM1 study who achieved an early (0 4 month) or late (>4 month) response to therapy* ( PR) were compared. Outcomes Median number treatment cycles Ixazomib-Rd Early (0 4 mos) n=174 Late (>4 mos) n=109 Early (0 4 mos) n=159 Placebo-Rd Late (>4 mos) n= Median PFS **, mos 18.5 NE 14.9 NE 50 5 Median DOR in PR pts, mos n=173 n=108 n=156 n= NE Premature discontinuation of therapy due to slow response should be avoided. Responding patients should stay on therapy until progressive disease or unacceptable toxicity. *Response was assessed every cycle based on central laboratory results and by IRC evaluation using IMWG criteria; **In patients with IRC-assessed best confirmed response; Analysed to address the possibility of guarantee-time bias. DOR, duration of response; mos, months; IMWG, International Myeloma Working Group; IRC, independent review committee; IRd, ixazomib-lenalidomide-dexamethasone; NE, not estimable; PFS, progression-free survival; PR, partial response; Rd, lenalidomide-dexamethasone. Garderet L et al. Blood 2016;128. Abstract 2134.
15 Second interim analysis: median follow-up of 23 months At 23 months follow-up, median OS had not yet been reached 1,2 Following achievement of the primary endpoint (PFS), a subsequent pre-specified interim analysis for OS was conducted deaths (only 35% of the required number of deaths for final OS analysis): 81 and 90 in the ixazomib and placebo regimens, respectively The median OS was not reached in either arm At the same time point, a non-inferential analysis of PFS was conducted 2 HR was 0.82 (95% CI: ) Median PFS was 20 months in the ixazomib regimen and 15.9 months in the placebo regimen CI, confidence interval; HR, hazard ratio; OS, overall survival; PFS, progression-free survival. 1. Moreau P et al. N Engl J Med 2016;374: ; 2. NINLARO (ixazomib capsules) Summary of Product Characteristics March 2017.
16 A continuation study of TOURMALINE-MM1 in China The China continuation study is a randomised, double-blind, placebocontrolled study conducted in China (n=115), with a similar study design and eligibility criteria as the TOURMALINE-MM1 study. This study evaluated the safety and efficacy of ixazomib-rd vs. placebo- Rd in adult RRMM patients from China Demographics Ixazomib-Rd (n=57) Placebo-Rd (n=58) Median age, years Gender, male/female, % 72/28 66/34 Number of prior lines of therapy, % or Prior PI, % Prior IMiD, % Prior stem cell transplant, % Relapsed *, % Refractory, % Relapsed and refractory, % High-risk cytogenetics, % NR NR ISS stage I or II, % ISS stage III, % 9 7 Creatinine clearance <60 ml/min 7 16 *Patients who had relapsed from at least one previous treatment but were not refractory to any previous treatment; Patients who were refractory to at least one previous treatment but were not relapsed to any previous treatment; Patients who were relapsed from at least one previous treatment and additionally were refractory to at least one previous treatment. Refractory disease was defined as disease progression on treatment or progression within 60 days after the last dose of a given therapy; Cytogenetics information was not available for the majority of patients and was thus not reported. OS, overall survival; PFS, progression-free survival; Rd, lenalidomide-dexamethasone; RRMM, relapsed/refractory multiple myeloma. Hou J et al. J Haematol Oncol 2017; doi: /s
17 A continuation study of TOURMALINE-MM1 in China showed improved OS in patients treated with ixazomib-rd vs. placebo-rd PFS and OS rates with ixazomib-rd were superior to those achieved with placebo-rd in Chinese patients with RRMM The OS benefit was consistent across subgroups defined by age, disease status and prior therapy exposure CI, confidence interval; HR, hazard ratio; OS, overall survival; PFS, progression-free survival; Rd, lenalidomide-dexamethasone; RRMM, relapsed/refractory multiple myeloma.
18 Efficacy summary Ixazomib when combined with Rd (an all-oral triplet regimen) was associated with: A significant and clinically meaningful improvement in PFS vs. placebo-rd months vs months, respectively; HR: 0.74; p=0.01 Similar median PFS in both high- and standard-risk cytogenetics patients 1, months vs months, respectively Significantly improved PFS vs. placebo-rd in patients who have received 2 or 3 prior lines of therapy 3 NE vs months, respectively; HR: 0.58 Responses deepened with continued ixazomib-rd treatment 1 A later response was not detrimental to overall outcome 5 Significantly improved OS vs. placebo-rd in a Chinese continuation study months vs months, respectively; HR: 0.42; p=0.001 HR, hazard ratio; NE, not estimable; PFS, progression-free survival; Rd, lenalidomide-dexamethasone; TTP, time to progression. 1. Moreau P et al. N Engl J Med 2016;374: ; 2. Avet-Loiseau H et al. European Hematology Association 22 nd Congress 2016; Poster P269.; 3. Mateos MV et al. Haematologica 2017; pii: haematol [E-pub ahead of print]; 4.Garderet L et al. Blood 2016;128. Abstract 2134; 5. Hou J et al. J Haematol Oncol 2017; doi: /s
19 TOURMALINE-MM1: Safety
20 Summary of treatment exposure and treatment-emergent adverse events Median follow-up: 23.3 months for ixazomib-rd and 22.9 months for placebo-rd Median number of treatment cycles: 17 (range 1 34) for ixazomib-rd, and 15 (1 34) for placebo-rd 48% and 43% of patients received 18 cycles in the ixazomib and placebo groups, respectively 20% and 19% of patients received 25 cycles in the ixazomib and placebo groups, respectively Adverse event (AE) Ixazomib-Rd (n=361), % Placebo-Rd (n=359), % Any AE Any grade 3 AE Any serious AE AE resulting in discontinuation of study regimen * On-study death (death within 30 days of last dose) 4 6 Higher frequency of grade 3 AEs, primarily due to thrombocytopenia Rates of AEs resulting in discontinuation or on-study death were similar between the two arms *Discontinuation of the study regimen was defined as discontinuation of the full study regimen and included discontinuation because of disease progression. AE, adverse event; Rd, lenalidomide-dexamethasone. Moreau P et al. N Engl J Med 2016;374:
21 Ixazomib-Rd was generally well tolerated with manageable side effects AEs after median follow-up of 23 months Ixazomib-Rd (n=361), % Placebo-Rd (n=359), % Preferred terms All grades Grade 3 Grade 4 All grades Grade 3 Grade 4 Diarrhoea Constipation 35 < <1 0 Nausea Fatigue Vomiting <1 0 Rash* Back pain 24 < Upper respiratory tract infection 23 < <1 0 Thrombocytopenia * Peripheral neuropathies* Peripheral oedema Thromboembolism* 8 2 < <1 Neutropenia* *Represents multiple MedDRA preferred terms. In addition, grade 5 arrhythmia was reported in two patients in the ixazomib group and in three patients in the placebo group; grade 5 thromboembolism was reported in one patient in each group; grade 5 hypotension was reported in one patient in the ixazomib group; grade 5 heart failure was reported in one patient in the ixazomib group and in three patients in the placebo group; and grade 5 myocardial infarction was reported in one patient in the ixazomib group and in two patients in the placebo group. AE, adverse event; Rd, lenalidomide-dexamethasone. Moreau P et al. N Engl J Med 2016;374:
22 Other infrequent adverse events: no safety concerns identified Median follow-up of 23 months Ixazomib-Rd (n=361), % Placebo-Rd (n=359), % Preferred terms All grades All grades Arrhythmias* Hypertension 6 5 Hypertensive crisis <1 0 Hypotension* 6 6 Heart failure* 4 4 Myocardial infarction* 1 2 Acute renal failure* 9 11 Liver impairment* 7 6 Interstitial lung disease* 1 2 Encephalopathy* <1 1 Events of special interest New primary malignancy*, 5 4 *Represents multiple MedDRA preferred terms; Includes treatment-emergent AEs and new primary malignancies reported during follow-up period; In addition, grade 5 arrhythmia was reported in two patients in the ixazomib group and in three patients in the placebo group; grade 5 thromboembolism was reported in one patient in each group; grade 5 hypotension was reported in one patient in the ixazomib group; grade 5 heart failure was reported in one patient in the ixazomib group and in three patients in the placebo group; and grade 5 myocardial infarction was reported in one patient in the ixazomib group and in two patients in the placebo group. Rd, lenalidomide-dexamethasone. Moreau P et al. N Engl J Med 2016;374:
23 Quality of life maintained with ixazomib-rd vs. placebo-rd: EORTC-QLQ-C30 Quality of life was maintained with the addition of ixazomib to a standard Rd regimen EORTC-QLQ-C30 Mean global health status score CI, confidence interval; EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Core 30 module; EOT, end of treatment; QoL, quality of life; Rd, lenalidomide-dexamethasone. Moreau P et al. N Engl J Med 2016;374:
24 Safety summary 1,2 Ixazomib added limited additional toxicity to that seen with placebo-rd Low rates of peripheral neuropathy: Grade 3 events (2%) similar to placebo-rd and no Grade 4 events 1 Numerically higher all-grade thrombocytopenia with ixazomib-rd (31%) vs. placebo-rd (16%) 1 Thrombocytopenia was not associated with increased rates of bleeding, clinically significant bleeding events, or increased rate of platelet transfusions 2 No cardiovascular, pulmonary or renal safety signals to date 1 Patient-reported quality of life was maintained with the addition of a third agent to standard doublet regimen 1 Rd, lenalidomide-dexamethasone. 1. Moreau P et al. N Engl J Med 2016;374: ; 2. NINLARO (ixazomib capsules) Summary of Product Characteristics March 2017.
25 Ixazomib-Rd: Dosing and administration
26 Ixazomib phase III dosing schedule day half-life; supported once-weekly dosing 1 Maximum tolerated dose of 2.97 mg/m 2 ; converted to 5.5 mg fixed dose 1,2 5.5 mg associated with improved response rates but higher toxicities than 4.0 mg 3 Pharmacokinetic studies Phase I dose escalation studies Phase II study TOURMALINE -MM1 The agreed phase III dosing schedule of ixazomib is 4.0 mg once weekly 1. Kumar SK et al. Blood 2014;124: ; 2. Kumar SK et al. Lancet Oncology 2014;15: ; 3. Kumar SK et al. Blood 2016; 128:
27 Ixazomib-Rd is taken as a 28-day treatment cycle cycles continue one after the other Each dose of ixazomib should be taken approximately the same time each day on an empty stomach (at least one hour before and two hours after food) Dexamethasone should be taken with food, therefore ixazomib and dexamethasone should not be taken at the same time Ixazomib should be swallowed whole with a glass of water the capsule should not be crushed, chewed or opened If a dose on ixazomib is missed or delayed, the dose should be taken only if the next scheduled dose is 72 hours away Rd, lenalidomide-dexamethasone. NINLARO (ixazomib capsules) Summary of Product Characteristics July 2017.
28 Summary Ixazomib-Rd demonstrated improved efficacy with limited additional toxicity compared to placebo-rd Ixazomib-Rd showed significant and clinically meaningful improvement in PFS vs. placebo-rd which was maintained following subgroup analysis for cytogenetic risk and 2 3 prior lines of therapy 1 3 Ixazomib-Rd significantly increased TTP compared to placebo-rd and demonstrated increased and deepening responses over time 1 Ixazomib-Rd treatment resulted in numerically greater rates of all grade peripheral neuropathy vs. placebo-rd (27% vs. 22%) but no increase in grade 3 events Thrombocytopenia of grade 3 or 4 severity occurred more frequently in the ixazomib group than in the placebo group, however, this was not associated with increased bleeding or platelet transfusions 1 A Chinese continuation study showed increased OS with ixazomib-rd compared to placebo-rd 4 Patient-reported quality of life was maintained with the addition of a ixazomib to Rd 1 OS, overall survival; PFS, progression-free survival; Rd, lenalidomide-dexamethasone; TTP, time to progression. 1. Moreau P et al. N Engl J Med 2016;374: ; 2. Avet-Loiseau H et al. European Hematology Association 22 nd Congress 2016; Poster P269; 3. Mateos MV et al. Haematologica 2017; pii: haematol [E-pub ahead of print]; 4. Hou J et al. J Haematol Oncol 2017; doi: /s
29 Abbreviated Prescribing Information: NINLARO (ixazomib) (Refer to Summary of Product Characteristics (SmPC) before prescribing) Presentation: Ixazomib 2.3 mg, 3 mg and 4 mg hard capsules. Indication: NINLARO in combination with lenalidomide and dexamethasone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. Dosage & Administration: Treatment must be initiated and monitored under the supervision of a physician experienced in the management of multiple myeloma. NINLARO should be used in combination with lenalidomide and dexamethasone. For additional information regarding lenalidomide and dexamethasone, refer to their SmPCs. The recommended starting dose of NINLARO is 4 mg (one capsule) administered orally once a week on Days 1, 8, and 15 of a 28-day treatment cycle at least 1 hour before or at least 2 hours after food. The recommended starting dose of lenalidomide is 25 mg administered daily on Days 1 to 21 of a 28-day treatment cycle. The recommended starting dose of dexamethasone is 40 mg administered on Days 1, 8, 15, and 22 of a 28-day treatment cycle. Prior to initiating a new cycle of therapy, absolute neutrophil count should be 1,000/mm 3, platelet count should be 75,000/mm 3, non-haematologic toxicities should, at the physician s discretion, generally be recovered to patient s baseline condition or Grade 1. Treatment should be continued until disease progression or unacceptable toxicity. Treatment with NINLARO in combination with lenalidomide and dexamethasone for longer than 24 cycles should be based on an individual benefit risk assessment, as the data on the tolerability and toxicity beyond 24 cycles are limited. Antiviral prophylaxis should be considered in patients being treated with NINLARO to decrease the risk of herpes zoster reactivation. Thromboprophylaxis is recommended in patients being treated with NINLARO in combination with lenalidomide and dexamethasone, and should be based on an assessment of the patient s underlying risks and clinical status. Elderly: No dose adjustment is necessary in patients over 65 years of age. Renal impairment: Mild or moderate renal impairment, no dose adjustment is necessary. Reduced 3 mg starting dose recommended in severe renal impairment or end-stage renal disease requiring dialysis. Hepatic impairment: Mild hepatic impairment, no dose adjustment is necessary. Reduced 3 mg starting dose recommended in moderate or severe hepatic impairment. Paediatric population: No data are available. Contraindications: Hypersensitivity to the active substance or to its excipients. Warnings & Precautions: Thrombocytopenia: Thrombocytopenia has been reported with NINLARO with platelet nadirs typically occurring between Days of each 28-day cycle and recovery to baseline by the start of the next cycle. Thrombocytopenia did not result in an increase in haemorrhagic events or platelet transfusions. Platelet counts should be monitored at least monthly during NINLARO treatment. Thrombocytopenia can be managed with dose modifications and platelet transfusions as per standard medical guidelines. Gastrointestinal toxicities: Diarrhoea, constipation, nausea and vomiting have been reported with NINLARO, occasionally requiring use of antiemetic and antidiarrhoeal medicinal products and supportive care. The dose should be adjusted for severe (Grade 3 4) symptoms. Peripheral neuropathy: Peripheral neuropathy has been reported with NINLARO. Patients should be monitored for symptoms of peripheral neuropathy. Patients experiencing new or worsening peripheral neuropathy may require dose modification. Peripheral oedema: Peripheral oedema has been reported with NINLARO. Patients should be evaluated for underlying causes and provide supportive care, as necessary. The dose of dexamethasone should be adjusted per its SmPC or NINLARO for Grade 3 or 4 symptoms. Cutaneous reactions: Rash has been reported with NINLARO. Rash should be managed with supportive care or with dose modification if Grade 2 or higher. Hepatotoxicity: Drug-induced liver injury, hepatocellular injury, hepatic steatosis, hepatitis cholestatic and hepatotoxicity have been uncommonly reported with NINLARO. Hepatic enzymes should be monitored regularly and the dose should be adjusted for Grade 3 or 4 symptoms. Pregnancy: Women should avoid becoming pregnant while being treated with NINLARO. Posterior reversible encephalopathy syndrome (PRES): PRES has occurred in patients receiving NINLARO. In patients developing PRES, discontinue NINLARO. Interactions: Strong cytochrome P450 (CYP) 3A inducers: Coadministration of strong CYP3A inducers with NINLARO is not recommended. Strong CYP3A inhibitors: No dose modification is required for NINLARO with co-administration of strong CYP3A inhibitors. Strong CYP1A2 inhibitors: No dose modification is required for NINLARO with co-administration of strong CYP1A2 inhibitors. Fertility, Pregnancy & Lactation: Women should avoid becoming pregnant while being treated with NINLARO. Male and female patients of childbearing potential must use effective contraceptive measures during and for 90 days following treatment. Women using oral hormonal contraceptives should additionally use a barrier method of contraception. No data from use in pregnant women. Avoid use during pregnancy. Unknown whether NINLARO/metabolites are excreted in human milk, a risk to newborns/infants cannot be excluded; therefore breast feeding should be discontinued. The effect of NINLARO on fertility in humans has not been studied. Undesirable Effects: (All grades) Very common ( 1/10): Upper respiratory tract infection, thrombocytopenia, neutropenia, peripheral neuropathies, diarrhoea, nausea, vomiting, constipation, rash, back pain and oedema peripheral. Common ( 1/100, <1/10): Herpes zoster. Outside of the Phase 3 study, the following serious adverse reactions were rarely ( 1/10,000 to < 1/1,000) reported: acute febrile neutrophilic dermatosis, Stevens- Johnson syndrome, transverse myelitis, posterior reversible encephalopathy syndrome, tumour lysis syndrome and thrombotic thrombocytopenic purpura. Refer to the SmPC for details on full side effect profile and interactions. Pharmaceutical Precautions: Do not store above 30 C. Do not freeze. Store in the original package in order to protect from moisture. PI Date of Preparation: Dec 2016 PI approval code: UK/IXA/1611/0096 Legal category: POM Basic NHS Price: 6336 for 3 capsules. Marketing Authorisation: EU/1/16/1094/001, EU/1/16/1094/002, EU/1/16/1094/003 Further information is available from: Takeda UK Ltd. Building 3, Glory Park, Glory Park Avenue, Wooburn Green, Buckinghamshire, HP10 0DF. Tel: Fax: NINLARO is a registered trademark of Takeda Pharmaceutical Company Limited. NINLARO has received a conditional marketing authorisation in Europe. A conditional marketing authorisation is granted to a medicinal product that fulfils an unmet medical need when the benefit to public health of immediate availability outweighs the risk inherent in the fact additional data are still required. The European regulatory agency will review new information on NINLARO at least every year and the summary of product characteristics will be updated as necessary. Please refer to the Summary of Product Characteristics for details on the full side-effect profile and drug interactions of NINLARO. Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to Takeda UK Ltd
Is sustained triplet therapy the new standard of care in relapsed/refractory multiple myeloma?
Takeda Oncology-sponsored satellite symposium at the British Society for Haematology (BSH) 57 th Annual Scientific Meeting Is sustained triplet therapy the new standard of care in relapsed/refractory multiple
More informationExpert perspectives real-world clinical experiences in relapsed myeloma
Takeda Oncology-sponsored satellite symposium at the British Society for Haematology (BSH) 57 th Annual Scientific Meeting Expert perspectives real-world clinical experiences in relapsed myeloma This satellite
More informationCurrent treatment options for relapsed/refractory multiple myeloma in practice
Current treatment options for relapsed/refractory multiple myeloma in practice Professor Marίa-Victoria Mateos University Hospital of Salamanca, Salamanca, Spain Please note that discussion throughout
More informationWARNINGS AND PRECAUTIONS
DOSING GUIDE INDICATION NINLARO (ixazomib) is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.
More informationNinlaro. (ixazomib) New Product Slideshow
Ninlaro (ixazomib) New Product Slideshow Introduction Brand name: Ninlaro Generic name: Ixazomib Pharmacological class: Proteasome inhibitor Strength and Formulation: 2.3mg, 3mg, 4mg; gel caps Manufacturer:
More informationIxazomib with Lenalidomide and Dexamethasone (IRd)
Indication Ixazomib, with lenalidomide and dexamethasone, is recommended for use within the Cancer Drugs Fund as an option for treating multiple myeloma for patients who have already had 2 or 3 lines of
More informationCOMy Congress The case for IMids. Xavier Leleu. Hôpital la Milétrie, PRC, CHU, Poitiers, France
Xavier Leleu Hôpital la Milétrie, PRC, CHU, Poitiers, France The case for IMids COMy Congress 21 Disclosures Grants/research support: Amgen, Bristol-Myers Squibb, Celgene, Janssen, Millennium/Takeda, Novartis,
More informationNovel treatment strategies for multiple myeloma: a focus on oral proteasome inhibitors
Novel treatment strategies for multiple myeloma: a focus on oral proteasome inhibitors Antonio Palumbo M.D. Takeda Pharmaceuticals International AG Introduction Multiple genetically-distinct subclones
More informationFOR IMMEDIATE RELEASE
FOR IMMEDIATE RELEASE FOR UK MEDICAL AND TRADE MEDIA ONLY Takeda Presents Data from TOURMALINE-MM1 Study for Ixazomib, the First and Only Once-Weekly Oral Proteasome Inhibitor Studied in Phase III Clinical
More informationProteasome inhibitor (PI) and immunomodulatory drug (IMiD) refractory multiple myeloma is associated with inferior patient outcomes
Alliance A061202. A phase I/II study of pomalidomide, dexamethasone and ixazomib versus pomalidomide and dexamethasone for patients with multiple myeloma refractory to lenalidomide and proteasome inhibitor
More informationDaratumumab: Mechanism of Action
Phase 3 Randomized Controlled Study of Daratumumab, Bortezomib and Dexamethasone (D) vs Bortezomib and Dexamethasone () in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): CASTOR* Antonio
More informationCarfilzomib and Dexamethasone (CarDex)
Carfilzomib and Dexamethasone (CarDex) Indication Relapsed multiple myeloma for patients who have had only one previous line of therapy (that did not include bortezomib). (NICE TA457) ICD-10 codes Codes
More informationHow to Integrate the New Drugs into the Management of Multiple Myeloma
How to Integrate the New Drugs into the Management of Multiple Myeloma Carol Ann Huff, MD The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins NCCN.org For Clinicians NCCN.org/patients For Patients
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked
More informationAntibodies are a standard part of first relapse management in multiple myeloma (MM): Yes
Antibodies are a standard part of first relapse management in multiple myeloma (MM): Yes Ajay Nooka, MD MPH FACP Assistant Professor, Division of Bone Marrow Transplant Winship Cancer Institute, Emory
More informationMethods: Studies included in the analysis
Efficacy and safety of long-term ixazomib maintenance therapy in patients with newly diagnosed multiple myeloma not undergoing transplant: An integrated analysis of four phase 1/2 studies Meletios A. Dimopoulos,
More informationCost-effectiveness of ixazomib (Ninlaro ) for the Treatment of Adult Patients with Multiple Myeloma who have Received at Least One Prior Therapy
Cost-effectiveness of ixazomib (Ninlaro ) for the Treatment of Adult Patients with Multiple Myeloma who have Received at Least One Prior Therapy The NCPE has issued a recommendation regarding the cost-effectiveness
More informationPanobinostat, Bortezomib and Dexamethasone
Panobinostat, Bortezomib and Dexamethasone Indication Treatment of relapsed/refractory multiple myeloma in patients who have received at least 2 prior regimens, including bortezomib and an immunomodulatory
More informationRegimen Protocols IRD or RID: Ixazomib citrate/lenalidomide/dexamethasone
Regimen Protocols IRD or RID: Ixazomib citrate/lenalidomide/dexamethasone Constituents of Regimen: ixazomib, lenalidomide, dexamethasone Other Names of Regimen Constituents and Unique Ingredient Identifier
More informationModel-Informed Drug Development (MIDD) for Ixazomib, an Oral Proteasome Inhibitor
Model-Informed Drug Development (MIDD) for Ixazomib, an Oral Proteasome Inhibitor Neeraj Gupta, Michael J. Hanley, Paul M. Diderichsen, 2 Huyuan Yang, Yeamin Huh, Alice Ke, 4 Zhaoyang Teng, Richard Labotka,
More informationClinicalTrials.gov Identifier: NCT
Efficacy of Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma Among Patients With to 3 Prior Lines of Therapy Based on
More informationPOMALYST (pomalidomide) for Previously Treated Multiple Myeloma
POMALYST (pomalidomide) for Previously Treated What is POMALYST? POMALYST (pomalidomide) capsule is an oral immunomodulatory therapy (a thalidomide analogue) indicated for patients with multiple myeloma
More informationPractical Considerations in Multiple Myeloma: Optimizing Therapy With New Proteasome Inhibitors
Welcome to Managing Myeloma. My name is Dr. Donald Harvey. I am Director of Phase 1 Clinical Trials Section and an Associate Professor in Hematology, Medical Oncology, and Pharmacology at the Winship Cancer
More informationNCCP Chemotherapy Regimen. Carfilzomib, Lenalidomide and Dexamethasone (KRd) Therapy - 28 day
, Lenalidomide and Dexamethasone (KRd) Therapy - INDICATIONS FOR USE: INDICATION ICD10 Regimen Code Reimbursement Status *, lenalidomide and dexamethasone therapy is indicated for the treatment of adult
More informationStandard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant
Standard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant Pr Philippe Moreau University Hospital, Nantes, France MP: Standard of care until 2007 J Clin Oncol
More informationNovel Treatment Advances and Approaches in Management of Relapsed/Refractory Multiple Myeloma
Novel Treatment Advances and Approaches in Management of Relapsed/Refractory Multiple Myeloma Ravi Vij, MD MBA Professor of Medicine Washington University School of Medicine Section of Stem Cell Transplant
More informationBortezomib, Thalidomide and Dexamethasone (VTD) 28 day
Bortezomib, Thalidomide and Dexamethasone (VTD) 28 day Indication First line treatment of multiple myeloma in patients who are eligible for stem cell transplantation. (NICE TA311) ICD-10 codes Codes with
More informationPRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION NINLARO
PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr NINLARO ixazomib (as ixazomib citrate) 4 mg, 3 mg and 2.3 mg capsules Antineoplastic Agent Takeda Canada Inc. 2201 Bristol Circle, Suite 700
More informationTo Maintain or Not to Maintain? Immunomodulators vs PIs Yes: Proteasome Inhibitors
To Maintain or Not to Maintain? Immunomodulators vs PIs Yes: Proteasome Inhibitors James Berenson, MD Institute for Myeloma and Bone Cancer Research West Hollywood, CA Financial Disclosures Takeda, Celgene
More informationDaratumumab: Mechanism of Action
An Open-label, Randomised, Phase 3 Study of Daratumumab, Lenalidomide, and Dexamethasone (D) Versus Lenalidomide and Dexamethasone () in Relapsed or Refractory Multiple Myeloma (RRMM): POLLUX* Meletios
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationTreatment Strategies for Transplant-ineligible NDMM Patients
1 Treatment Strategies for Transplant-ineligible NDMM Patients Thierry Facon, MD Professor of Hematology Service des Maladies du Sang University of Lille Lille, France Multiple Myeloma affects primarily
More informationUpdate on Multiple Myeloma Treatment
Update on Multiple Myeloma Treatment Professor Chng Wee Joo Director National University Cancer Institute of Singapore (NCIS) National University Health System (NUHS) Deputy Director Cancer Science Institute,
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked
More informationDOSING FLEXIBILITY OF REVLIMID
REVLIMID Dose Adjustments for Renal Impairment DISCOVER THE DOSING FLEXIBILITY OF REVLIMID FOR PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) REVLIMID (lenalidomide) is indicated for the treatment of patients
More informationPomalidomide and Dexamethasone Therapy
INDICATIONS FOR USE: Pomalidomide and Therapy Regimen Code INDICATION ICD10 Treatment in combination with dexamethasone of adult patients with relapsed and refractory multiple myeloma who have received
More informationMultiple Myeloma: Induction, Consolidation and Maintenance Therapy
Multiple Myeloma: Induction, Consolidation and Maintenance Therapy James R. Berenson, MD Medical & Scientific Director Institute for Myeloma & Bone Cancer Research Los Angeles, CA Establish the Goals of
More informationMyeloma update ASH 2014
Myeloma update ASH 2014 Updates in Newly Diagnosed Multiple Myeloma FIRST: effect of age on lenalidomide/dexamethasone vs MPT in transplantation-ineligible pts Phase III: MPT-T vs MPR-R in transplantation-ineligible
More informationTreatment of elderly multiple myeloma patients
SAMO Interdisciplinary Workshop on Myeloma March 30 th -31 st 2012, Seehotel Hermitage, Lucerne Treatment of elderly multiple myeloma patients Federica Cavallo, MD, PhD Federica Cavallo, MD, PhD Division
More informationPomalidomide and Dexamethasone INDICATIONS FOR USE:
Pomalidomide and INDICATIONS FOR USE: INDICATION Treatment in combination with dexamethasone of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment
More informationDOSING FLEXIBILITY OF REVLIMID
REVLIMID Dose Adjustments for Thrombocytopenia DISCOVER THE DOSING FLEXIBILITY OF REVLIMID FOR PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) REVLIMID (lenalidomide) is indicated for the treatment of patients
More informationTREATING RELAPSED / REFRACTORY MYELOMA AT THE LEADING EDGE
TREATING RELAPSED / REFRACTORY MYELOMA AT THE LEADING EDGE PRESENTED BY: Pooja Chaukiyal MD Hematologist/Oncologist New York Oncology Hematology Albany, NY April 16, 2016 Background The prognosis for patients
More informationPomalidomide (CC4047) Plus Low-Dose Dexamethasone as Therapy for Relapsed Multiple Myeloma. Lacy MQ et al. J Clin Oncol 2009;27(30):
Pomalidomide (CC4047) Plus Low-Dose Dexamethasone as Therapy for Relapsed Multiple Myeloma Lacy MQ et al. J Clin Oncol 2009;27(30):5008-14. Introduction A curative therapy for multiple myeloma (MM) does
More informationHighlights from EHA Mieloma Multiplo
Highlights from EHA Mieloma Multiplo Michele Cavo Istituto di Ematologia L. e A. Seràgnoli Alma Mater Studiorum Università degli studi di Bologna Firenze, 22-23 Settembre 27 Myeloma XI TE pathway 7 R :
More informationUnmet Medical Needs and Latest Multiple Myeloma Treatment
Unmet Medical Needs and Latest Multiple Myeloma Treatment Professor Chng Wee Joo Director National University Cancer Institute of Singapore (NCIS) National University Health System (NUHS) Deputy Director
More informationCME Information LEARNING OBJECTIVES
CME Information LEARNING OBJECTIVES Identify patients with MM who have undergone autologous stem cell transplant and would benefit from maintenance lenalidomide. Counsel older patients (age 65 or older)
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab therapy
More informationBortezomib and Dexamethasone Therapy INDICATIONS FOR USE:
Bortezomib and Dexamethasone Therapy INDICATIONS FOR USE: INDICATION Treatment of adult patients with progressive multiple myeloma who have received at least one prior therapy ICD10 C90 Protocol Code 00270a
More information* Dose may vary dependent on tolerability and co-morbidities
BC Cancer Protocol Summary for Treatment of Previously Untreated Multiple Myeloma and Not Eligible for Stem Cell Transplant Using Lenalidomide with Low-dose Dexamethasone Protocol Code Tumour Group Contact
More informationUK MRA Myeloma XII Relapsed Intensive Study CI: Prof Gordon Cook
UK Myeloma Research Alliance Myeloma XII study (ACCoRD): Augmented Conditioning & Consolidation in Relapsed Disease UK MRA Myeloma XII Relapsed Intensive Study CI: Prof Gordon Cook Sponsor ID: Pending
More informationClinicalTrials.gov Identifier: NCT
Efficacy of Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma Based on Prior Lines of Therapy: Updated Analysis of CASTOR Maria-Victoria
More informationA Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car- Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma
A Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car- Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma Jatin J. Shah, MD 1, Edward A. Stadtmauer, MD 2, Rafat
More informationLong-term ixazomib maintenance is tolerable and improves depth of response following ixazomiblenalidomide-dexamethasone
Long-term ixazomib maintenance is tolerable and improves depth of response following ixazomiblenalidomide-dexamethasone induction in patients with previously untreated multiple myeloma (MM): Phase 2 study
More informationCREDIT DESIGNATION STATEMENT
CME Information LEARNING OBJECTIVES Integrate emerging research information on the use of proteasome inhibitors and immunomodulatory agents to individualize induction treatment recommendations and maintenance
More informationBCCA Protocol Summary for Therapy of Multiple Myeloma Using Pomalidomide with Dexamethasone
BCCA Protocol Summary for Therapy of Multiple Myeloma Using Pomalidomide with Dexamethasone Protocol Code UMYPOMDEX Tumour Group Contact Physician Contact Pharmacist Lymphoma, Leukemia/BMT Dr. Kevin Song
More informationProgress in Multiple Myeloma
Progress in Multiple Myeloma Sundar Jagannath, MD Professor, New York Medical College Adjunct Professor, New York University St. Vincent s Comprehensive Cancer Center, NY Faculty Disclosure Advisory Board:
More informationDisclosures. Membership of Advisory Committees: Research Support/ PI: Celgene Corporation Millennium Pharmaceuticals Johnson & Johnson
Randomized, Open-Label Phase 1/2 Study of Pomalidomide Alone or in Combination With Low-Dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That
More informationA Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car- Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma
A Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car- Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma Jatin J. Shah, MD 1, Edward A. Stadtmauer, MD 2, Rafat
More informationPhase 1 Study of ARRY-520 and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
Phase 1 Study of ARRY-520 and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Jatin J Shah, MD, Sheeba Thomas, MD, Donna Weber, MD, Michael Wang, MD, Raymond Alexanian, MD, Robert
More informationTREATMENT FOR NON-TRANSPLANT ELIGIBLE MULTIPLE MYELOMA
TREATMENT FOR NON-TRANSPLANT ELIGIBLE MULTIPLE MYELOMA Ekarat Rattarittamrong, MD Division of Hematology Department of Internal Medicine Faculty of Medicine Chiang Mai University OUTLINE Overview of treatment
More informationCyBorD/ Cylophosphamide, Bortezomib, and
CyBorD/ Cylophosphamide, Bortezomib, and Dexamethasone-21 day Therapy i INDICATIONS FOR USE: INDICATION ICD10 Protocol Code Treatment of newly diagnosed symptomatic multiple myeloma i C90 00273a Treatment
More informationDaratumumab: Mechanism of Action
Phase 3 Randomized Controlled Study of Daratumumab, Bortezomib and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): CASTOR* Antonio
More informationSUBCUTANEOUS Bortezomib + Thalidomide +Dexamethasone Available for Routine Use in
SUBCUTANEOUS Bortezomib + Thalidomide +Dexamethasone Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community Burton out-patient Derby
More informationManaging Major Adverse Events in Relapsed/Refractory Multiple Myeloma
Welcome to Managing Myeloma. I am Dr. Ajay Nooka. In today's presentation, I will discuss managing major adverse events in relapsed/refractory multiple myeloma. In this video, I will provide you with information
More informationSkin Pathway Group Alemtuzumab in Cutaneous Lymphoma
Skin Pathway Group Alemtuzumab in Cutaneous Lymphoma Indication: Treatment of patients with Cutaneous Lymphoma (Unlicensed use) Disease control prior to Reduced Intensity Conditioning Stem Cell Transplant
More informationMULTIPLE MYELOMA AFTER AGE OF 80 YEARS
MULTIPLE MYELOMA AFTER AGE OF 80 YEARS C. Hulin CHU Nancy, France Intergroupe Francophone du Myelome (IFM) Epidemiology SEER Program between 1990-2004: 17 330 MM cases, 51% 70 y and 20% 80 y. Brenner et
More informationfrom 20 February 2014
Resolution by the Federal Joint Committee on an amendment to the Pharmaceutical Directive (AM-RL): Appendix XII - Resolutions on the benefit assessment of pharmaceuticals with new active ingredients, in
More informationSmoldering Myeloma: Leave them alone!
Smoldering Myeloma: Leave them alone! David H. Vesole, MD, PhD Co-Director, Myeloma Division Director, Myeloma Research John Theurer Cancer Center Hackensack University Medical Center Prevalence 1960 2002
More informationUpdate: Chronic Lymphocytic Leukemia
ASH 2008 Update: Chronic Lymphocytic Leukemia Improving Patient Response to Treatment with the Addition of Rituximab to Fludarabine-Cyclophosphamide ASH 2008: Update on chronic lymphocytic leukemia CLL-8
More informationInitial Therapy For Transplant-Eligible Patients With Multiple Myeloma. Michele Cavo, MD University of Bologna Bologna, Italy
Initial Therapy For Transplant-Eligible Patients With Multiple Myeloma Michele Cavo, MD University of Bologna Bologna, Italy Treatment Paradigm for Autotransplant-Eligible Patients With Multiple Myeloma
More informationBCCA Protocol Summary for Therapy of Relapsed Multiple Myeloma Using Lenalidomide with Dexamethasone
BCCA Protocol Summary for Therapy of Relapsed Multiple Myeloma Using Lenalidomide with Dexamethasone Protocol Code Tumour Group Contact Physician Contact Pharmacist UMYLDREL Lymphoma, Leukemia/BMT Dr.
More informationDisclosures. Consultancy, Research Funding and Speakers Bureau: Celgene Corporation, Millennium, Onyx, Cephalon
Pomalidomide With or Without Low-dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma: Outcomes in Patients Refractory to Lenalidomide and Bortezomib Ravi Vij 1, Paul G. Richardson
More informationLiving Well with Myeloma Teleconference Series Thursday, March 24 th :00 PM Pacific/5:00 PM Mountain 6:00 PM Central/7:00 PM Eastern
Living Well with Myeloma Teleconference Series Thursday, March 24 th 216 4: PM Pacific/5: PM Mountain 6: PM Central/7: PM Eastern Speakers Dr. Brian Durie, IMF Chairman Cedars Sinai Samuel Oschin Cancer
More informationASCO Analyst & Investor Webcast. June 1, 2018
ASCO Analyst & Investor Webcast June 1, 2018 June 1, 2018 NASDAQ: BLUE Forward Looking Statements These slides and the accompanying oral presentation contain forward-looking statements and information
More informationBC Cancer Protocol Summary for Maintenance Therapy of Multiple Myeloma Using Lenalidomide
BC Cancer Protocol Summary for Maintenance Therapy of Multiple Myeloma Using Lenalidomide Protocol Code Tumour Group Contact Physician Contact Pharmacist UMYLENMTN Lymphoma, Leukemia/BMT Dr. Kevin Song
More informationNCCP Chemotherapy Regimen. Ibrutinib Therapy Mantle Cell Lymphoma
INDICATIONS FOR USE: Ibrutinib Therapy Mantle Cell Lymphoma INDICATION ICD10 Regimen Code *Reimbursement Indicator As a single agent for the treatment of adult patients with relapsed or refractory mantle
More informationDana-Farber Cancer Institute, Boston, MA, USA; 2. H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA; 3
The investigational agent MLN9708, an oral proteasome inhibitor, in patients with relapsed and/or refractory multiple myeloma (MM): results from the expansion cohorts of a phase 1 dose-escalation study
More informationKyprolis is available as a single-use vial containing 10 mg, 30 mg or 60 mg of carfilzomib.
Kyprolis (carfilzomib) Powder for Injection Product Information Page 1 of 32 AUSTRALIAN PRODUCT INFORMATION KYPROLIS (CARFILZOMIB) 1 NAME OF THE MEDICINE Kyprolis is the registered trademark of Onyx Pharmaceuticals,
More informationIMiDs (Immunomodulatory drugs) and Multiple Myeloma
www.comtecmed.com/comy comy@comtecmed.com IMiDs (Immunomodulatory drugs) and Multiple Myeloma Xavier Leleu Service des Maladies du Sang Hôpital Huriez, CHRU, Lille, France www.comtecmed.com/comy comy@comtecmed.com
More informationSummary of the risk management plan (RMP) for Kyprolis (carfilzomib)
EMA/639793/2015 Summary of the risk management plan (RMP) for Kyprolis (carfilzomib) This is a summary of the risk management plan (RMP) for Kyprolis, which details the measures to be taken in order to
More informationH. Lee Moffitt Cancer Center and Research Institute, University of California, San Francisco & Tisch Cancer Institute, Mount Sinai School of Medicine
Pomalidomide, Cyclophosphamide, and Dexamethasone Is Superior to Pomalidomide and Dexamethasone in Relapsed and Refractory Myeloma: Results of a Multicenter Randomized Phase II Study Rachid Baz, Thomas
More informationMultiple Myeloma Updates 2007
Multiple Myeloma Updates 2007 Brian Berryman, M.D. Multiple Myeloma Updates 2007 Goals for today: Understand the staging systems for myeloma Understand prognostic factors in myeloma Review updates from
More informationBR is an established treatment regimen for CLL in the front-line and R/R settings
Idelalisib plus bendamustine and rituximab (BR) is superior to BR alone in patients with relapsed/refractory CLL: Results of a phase III randomized double-blind placebo-controlled study Andrew D. Zelenetz,
More informationScottish Medicines Consortium
Scottish Medicines Consortium lenalidomide, 5mg,10mg,15mg and 25mg capsules (Revlimid) No. (441/08) Celgene Europe Limited 04 April 2008 The Scottish Medicines Consortium has completed its assessment of
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked
More informationSafety profile of Liraglutide: Recent Updates. Mohammadreza Rostamzadeh,M.D.
Safety profile of Liraglutide: Recent Updates Mohammadreza Rostamzadeh,M.D. Pancreatitis: Victoza post-marketing experience: spontaneous reports of pancreatitis For the majority of the cases, there is
More informationMabThera. SC. The wait is over. MabThera delivered in just 5 minutes. SC= subcutaneous injection
MabThera SC. The wait is over. MabThera delivered in just 5 minutes Abbreviated Prescribing Information MabThera 1400 mg solution for subcutaneous (SC) injection (Rituximab) Indications: Indicated in adults
More informationWARNING, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS,
Celgene Corporation 86 Morris Avenue Summit, New Jersey 07901 Tel 908-673-9000 Fax 908-673-9001 October 2012 NEW Indication Announcement for ABRAXANE for Injectable Suspension (paclitaxel protein-bound
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationCuring Myeloma So Close and Yet So Far! Luciano J. Costa, MD, PhD Associate Professor of Medicine University of Alabama at Birmingham
Curing Myeloma So Close and Yet So Far! Luciano J. Costa, MD, PhD Associate Professor of Medicine University of Alabama at Birmingham What is cure after all? Getting rid of it? Stopping treatment without
More informationNCCP Chemotherapy Regimen
INDICATIONS FOR USE: Azacitidine i INDICATION ICD10 Regimen Code *Reimbursement Status Intermediate-1 and low risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System
More informationPrimary Endpoint The primary endpoint is overall survival, measured as the time in weeks from randomization to date of death due to any cause.
CASE STUDY Randomized, Double-Blind, Phase III Trial of NES-822 plus AMO-1002 vs. AMO-1002 alone as first-line therapy in patients with advanced pancreatic cancer This is a multicenter, randomized Phase
More informationDr Shankara Paneesha. ASH Highlights Department of Haematology & Stem cell Transplantation
ASH Highlights 2015 Themes of ASH 2015 Novel therapies - Myeloma AML Lymphoma Pd-L1 & PD-l inhibitors Emerging concepts in biology HIF-1a pathway Cautionary tales ASH Choosing Wisely list IFM/DFCI
More informationModified CyBorD/ Bortezomib, Cylophosphamide and Dexamethasone Weekly Therapy i
Modified CyBorD/ Bortezomib, Cylophosphamide and Weekly Therapy i INDICATIONS FOR USE: INDICATION ICD10 Protocol Code Treatment of newly diagnosed symptomatic multiple myeloma i C90 00299a Treatment of
More informationModified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment
ORIGINAL ARTICLE 218 Oct 26. [Epub ahead of print] https://doi.org/1.394/kjim.218.144 Modified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment
More informationDisclosures for Palumbo Antonio, MD
Disclosures for Palumbo Antonio, MD Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Honoraria Scientific Advisory Board o relevant conflicts of interest to declare o relevant
More informationKEYTRUDA is also indicated in combination with pemetrexed and platinum chemotherapy for the
FDA-Approved Indication for KEYTRUDA (pembrolizumab) in Combination With Carboplatin and Either Paclitaxel or Nab-paclitaxel for the Firstline Treatment of Patients With Metastatic Squamous Non Small Cell
More informationOncology Highlights ASCO 2011 MULTIPLE MYELOMA
Oncology Highlights ASCO 211 MULTIPLE MYELOMA July 211 Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Joseph Mikhael, MD, MEd, FRCPC Staff Hematologist, Mayo Clinic Arizona Disclosures
More informationREVLIMID Dosing Guide
REVLIMID Dosing Guide Convenient Once-Daily Oral Dosing for MM, MCL, and MDS 1 REVLIMID (lenalidomide) in combination with dexamethasone (dex) is indicated for the treatment of patients with multiple myeloma
More information